Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
申请人:Roche Diagnostics GmbH
公开号:US06472396B1
公开(公告)日:2002-10-29
Compounds of formula I, useful as matrix metalloprotease inhibitors,
wherein
X, Y and Z are each oxygen;
R1 is selected from the group consisting of (a) n-octyl, (b) n-decyl, (c) biphenyl and (d) (4-phenoxy)phenyl, wherein the terminal monocycle for moieties (c)-(d) is unsubstituted or substituted by a substituent selected from the group consisting of —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl, hydroxy, methoxy, ethoxy, cyano and halogen;
R2 and R3 are each hydrogen; and
R4 and R5, together with the nitrogen atom to which they are bound, form a piperazinyl or piperidyl ring, wherein the piperazinyl ring is substituted in the 4-position with a substituent selected from the group consisting of (a) a 6-membered aromatic monocycle having 0, 1 or 2 nitrogen atoms and the remainder of the atoms in the monocycle being carbon and (b) hydroxy-C1-C6 alkyl, wherein the monocycle is unsubstituted or substituted by a substituent selected from the group consisting of halogen, —NH2, —NO2, —SO2NH2, —SO2CH3, acetyl and cyano.
化合物I的式子,可用作基质金属蛋白酶抑制剂,其中X、Y和Z均为氧;R1选自(a)正辛基,(b)正癸基,(c)联苯基和(d)(4-苯氧基)苯基,其中对于基团(c)-(d)的末端单环可以是未取代的或取代的,所取代基团选自—NH2,—NO2,—SO2NH2,—SO2CH3,乙酰基,羟基,甲氧基,乙氧基,氰基和卤素;R2和R3均为氢;R4和R5与它们所连接的氮原子一起形成哌嗪基或哌啶基环,其中哌嗪基环在4位上被选自以下基团的取代基所取代:(a)具有0、1或2个氮原子和单环中其余原子为碳的6-成员芳香单环和(b)羟基-C1-C6烷基,其中单环未取代或被选自卤素,—NH2,—NO2,—SO2NH2,—SO2CH3,乙酰基和氰基的取代基所取代。